Want to create an interactive transcript for this episode?
Podcast: Clinician's Roundtable
Episode: Phase 3 study results of plozasiran in patients with FCS
Description:
Host: Gerald Watts, MD, PhD
There is a high unmet need for patients with persistent chylomicronemia. Plozasiran (ARO-APOC3) is an investigational drug that is being evaluated for these patients. Professor Gerald Watts shares the outcomes of the PALISADE trial, in which the efficacy and safety of plozasiran was examined in patients with familial chylomicronemia syndrome.